{"schema_version":"secwatch.filing_event.v1","accession":"0001555280-24-000295","form_type":"8-K","ticker":"ZTS","cik":"0001555280","company_name":"Zoetis Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.496786+00:00","generated_at":"2026-05-31T12:15:34.171068+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zoetis Q2 2024: revenue $2.4B (+11% op), adj EPS $1.56 (+20% op), raises FY guidance","bullets":["Revenue $2.4B, +8% reported / +11% operational; U.S. +12%, International +10% op.","GAAP net income $624M (-7%), diluted EPS $1.37 (-6%).","Adjusted net income $711M (+9% reported, +18% operational), adjusted diluted EPS $1.56 (+11% reported, +20% operational).","FY2024 guidance raised: revenue $9.100-9.250B, adj EPS $5.78-5.88; op rev growth 9-11%, op adj NI growth 13.5-15.5%.","Growth led by mAb OA pain products Librela/Solensia, Simparica Trio, and dermatology portfolio Apoquel/Cytopoint."],"urls":{"canonical":"https://secwatch.observer/filing/0001555280-24-000295","json":"https://secwatch.observer/filing/0001555280-24-000295.json","markdown":"https://secwatch.observer/filing/0001555280-24-000295.md","text":"https://secwatch.observer/filing/0001555280-24-000295.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1555280/000155528024000295/0001555280-24-000295-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1555280/000155528024000295/zts-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:15:34.171068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}